Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Assets (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Non-Current Assets for 5 consecutive years, with $42.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 153.62% to $42.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $132.2 million through Dec 2025, up 368.09% year-over-year, with the annual reading at $42.8 million for FY2025, 153.62% up from the prior year.
  • Non-Current Assets hit $42.8 million in Q4 2025 for ARS Pharmaceuticals, up from $33.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $51.1 million in Q1 2022 to a low of $265000.0 in Q3 2022.
  • Historically, Non-Current Assets has averaged $15.8 million across 5 years, with a median of $4.0 million in 2021.
  • Biggest five-year swings in Non-Current Assets: tumbled 99.44% in 2022 and later soared 2508.79% in 2025.
  • Year by year, Non-Current Assets stood at $716000.0 in 2021, then surged by 421.65% to $3.7 million in 2022, then crashed by 60.86% to $1.5 million in 2023, then surged by 1053.08% to $16.9 million in 2024, then surged by 153.62% to $42.8 million in 2025.
  • Business Quant data shows Non-Current Assets for SPRY at $42.8 million in Q4 2025, $33.9 million in Q3 2025, and $32.0 million in Q2 2025.